Limitations and challenges in treatment of acute chemical warfare agent poisoning.
about
Medical countermeasures for unwanted CBRN exposures: Part I chemical and biological threats with review of recent countermeasure patents.Imidazole aldoximes effective in assisting butyrylcholinesterase catalysis of organophosphate detoxification.A comprehensive evaluation of the efficacy of leading oxime therapies in guinea pigs exposed to organophosphorus chemical warfare agents or pesticides.Respiratory complications of organophosphorus nerve agent and insecticide poisoning. Implications for respiratory and critical care.Catalytic efficiencies of directly evolved phosphotriesterase variants with structurally different organophosphorus compounds in vitro.Assessing the therapeutic efficacy of oxime therapies against percutaneous organophosphorus pesticide and nerve agent challenges in the Hartley guinea pig.Detoxification of Organophosphate Poisoning Using Nanoparticle BioscavengersMustard vesicating agent-induced toxicity in the skin tissue and silibinin as a potential countermeasure.Limitations in current acetylcholinesterase structure-based design of oxime antidotes for organophosphate poisoning.Activation of the chemosensing transient receptor potential channel A1 (TRPA1) by alkylating agents.Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead.Essential Lessons in a Potential Sarin Attack Disaster Plan for a Resource-Constrained Environment.In vitro evaluation of the catalytic activity of paraoxonases and phosphotriesterases predicts the enzyme circulatory levels required for in vivo protection against organophosphate intoxications.Detection and remediation of organophosphorus compounds by oximate containing organogels.Decontamination and Remediation of the Sulfur Mustard Simulant CEES with "Off-the-Shelf" Reagents in Solution and Gel States: A Proof-of-Concept Study.Sulfur mustard induced mast cell degranulation in mouse skin is inhibited by a novel anti-inflammatory and anticholinergic bifunctional prodrug.Experiences of civilian nurses in triage during the Iran-Iraq War: An oral history.Chemical warfare in the First World War: reflections 100 years later.N-Acetyl-L-cysteine inhibits sulfur mustard-induced and TRPA1-dependent calcium influx.Evaluation of acetylcholine, seizure activity and neuropathology following high-dose nerve agent exposure and delayed neuroprotective treatment drugs in freely moving rats.In vivo protection studies of bis-quaternary 2-(hydroxyimino)-N-(pyridin-3-yl) acetamide derivatives against sarin poisoning in mice.Bioanalytical verification of V-type nerve agent exposure: simultaneous detection of phosphonylated tyrosines and cysteine-containing disulfide-adducts derived from human albumin.Identification of novel disulfide adducts between the thiol containing leaving group of the nerve agent VX and cysteine containing tripeptides derived from human serum albumin.Kinetic analysis of oxime-assisted reactivation of human, Guinea pig, and rat acetylcholinesterase inhibited by the organophosphorus pesticide metabolite phorate oxon (PHO).Reversible cholinesterase inhibitors as pre-treatment for exposure to organophosphates: assessment using azinphos-methyl.High-Throughput Screening for Positive Allosteric Modulators Identified Potential Therapeutics against Acetylcholinesterase Inhibition.Anticonvulsant discovery through animal models of status epilepticus induced by organophosphorus nerve agents and pesticides.Evaluating the broad-spectrum efficacy of the acetylcholinesterase oximes reactivators MMB4 DMS, HLö-7 DMS, and 2-PAM Cl against phorate oxon, sarin, and VX in the Hartley guinea pigSupramolecular gels for the remediation of reactive organophosphorus compounds
P2860
Q30245600-F11B9DBF-0E65-4B21-821D-5A1585513818Q34202608-DE5FB49D-900B-4E07-8F49-F2B84B99D484Q34628506-78C4DACB-4F9B-4D5E-AD21-1C2C3B9C4B8AQ34987201-AB13BA9C-7819-4A78-95A0-2F4862EAECD3Q35854206-51F7E03F-C669-4B23-8840-E6459D6FA57AQ36561465-5E435AB7-770C-42B4-BAD4-F565C33097AFQ36801498-037D2DD9-4A7C-42A4-BD6D-71E403A09303Q37083553-3FF7A7C4-FF71-4FFB-A3E1-4DDE93F8C9E9Q38884086-325F9A7D-51FE-49A6-BDC0-D5AAAD8B2238Q38940552-DEE17886-CEC2-423C-BBF3-84E9137CF2E5Q39004225-7A7BE418-0D09-42E0-A938-2FDF43C54D51Q39155547-708FF147-F88F-41B3-8E6D-8AA09BD95941Q39779108-3B06539D-A531-40A0-9D2F-C1C7E6983E9EQ41128111-88BF1944-45C1-4B97-B7B8-E48D0EECB484Q41239450-FC41B3EF-0844-4F33-ADB4-4482CB17901EQ47615630-DB7FE402-F100-4119-B910-4A76B853BA9CQ47792958-88D2D706-BB51-4654-8A79-E8CA669707E0Q48064872-ED3E8F36-7B71-48FC-8E87-EDB637FA040FQ48302303-898E55D9-ABD3-4375-8DBF-8BF0AB8C96BCQ48663292-7B2F49BB-6977-40B3-A794-D7DD317EAB1FQ48847157-93A9F84A-00F4-46C0-A0CB-4B54DBB7C2DFQ50098394-C29E1BFF-8D42-453E-B2D4-2B71A9BDFED9Q51276834-496E7789-FB41-4794-8C7F-D1ADB80AFB83Q51767129-25D245AC-F3C4-4AD5-9A47-1B7444EF8CF3Q52778422-98C1C6F4-1DC4-4467-AEE7-24D53D757298Q53716874-ACBB2D17-E283-4AE7-A873-FFB7BCC6DE41Q53761234-89B8AD3A-7C1A-43FD-B598-011263EB08B6Q57095530-6BA5E06C-7A37-4F73-A208-E4EBA71FC203Q57375080-9FB7A9AF-2014-483E-B968-15736D3E0BAA
P2860
Limitations and challenges in treatment of acute chemical warfare agent poisoning.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Limitations and challenges in treatment of acute chemical warfare agent poisoning.
@ast
Limitations and challenges in treatment of acute chemical warfare agent poisoning.
@en
type
label
Limitations and challenges in treatment of acute chemical warfare agent poisoning.
@ast
Limitations and challenges in treatment of acute chemical warfare agent poisoning.
@en
prefLabel
Limitations and challenges in treatment of acute chemical warfare agent poisoning.
@ast
Limitations and challenges in treatment of acute chemical warfare agent poisoning.
@en
P1476
Limitations and challenges in treatment of acute chemical warfare agent poisoning.
@en
P2093
Horst Thiermann
P304
P356
10.1016/J.CBI.2013.09.015
P577
2013-09-30T00:00:00Z